header-10.jpg
Translational Research

Presentations 2018

In 2018, APCRC-Q researchers presented the following orals and posters at national and international conferences:

The 2018 Australian Prostate Cancer Conference, Brisbane, 22-24 August 2018

Invited speaker:A/Prof Jyotsna Batra, A functional variation in PSA (KLK3) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with Prostate Cancer.

Invited speaker: Ms Panchadsaram Janaththani, Functional analysis of GWAS identified 5p15 locus in Prostate Cancer

Invited speaker: Dr Saeid Alinezhad, In Vitro Culture and Therapeutic Profiling of Patient Derived Metastatic Prostate Cancer

Invited speaker: Dr Brett Hollier, Tumour plasticity as a therapeutic target in advanced Prostate Cancer

Invited speaker: Dr Jennifer Gunter, Targeting Prostate Cancer cell metabolism with biguanides

Invited speaker: Ms Michelle Maugham, NTSR1 promotes aggressive Prostate Cancer growth in metabolic syndrome

Invited speaker: Dr Martin Sadowski, The fat side of Enzalutamide

Invited speaker: Ms Lisa Philip, Targeting Leptin Receptor Signalling Slows the Progression of Advanced Prostate Cancer

Invited speaker: Dr Ati Taherian Fard, Systems biology exploration of the temporal dynamics of plasticity

Poster: Philp LK, Rockstroh A, Tevz G, Taherian Fard A, Gunter JH, Wade J, Sadowski MC, Otvos Jr L, Nelson CC. Targeting Leptin Receptor Signalling Slows the Progression of Advanced Prostate Cancer

Poster: Gunter JH, Philp L, Rhee H, Lee W, Hollier B, Lehman M, Sadowski MC, Nelson C. Comparing adaptive prostate cancer cell metabolism following anti-androgen and biguanide treatment

Poster: Sweeney K, Taherian Fard A, Upadhyaya A, Stylianou N, Tevz G, Rockstroh A, Fazil L, McPherson S, Pirlo K, Ratther E, Lehman M, Wang Y, Gleave M, Nelson CC,  Hollier BG. The role of ZEB in the adaptive response to ATT-mediated development of neuroendocrine prostate cancer.

Poster: Tousignant K, Talebi A, Rockstroh A, Atefeh Fard A, Poad B, Gupta R, Gunter J, Swinnen J, Blanksby S, Nelson C and Sadowski M. Enhanced lipid uptake and lipid remodelling are adaptive responses to androgen-targeted therapies in prostate cancer.

Poster: Ratther E, Sweeney K, Hu Q, Rockstroh A, Lehman M, Wang C, Bartonicek N, Stylianou N, Tvez G, Nelson CC, Williams ED and Hollier BG. Investigating androgen deprivation and enzalutamide-mediated epithelial plasticity in prostate cancer progression.

Poster: Yeh MC, Tse BWC, Fletcher NL, Zachary H Huston, Chelsea Stewart, Kamil Sokolowski, Varinder Jeet, Sandra Wissmueller, Thurecht KJ, Campbell DH, Walsh BJ, Nelson CC, Russell PJ. Targeted beta therapy of human prostate cancer in vivo with Lu- labelled MIL- antibody against glypican- (GPC-).

Poster: Jeet V, Rockstroh A, Yeh MC, Campbell DH, Walsh BJ, Russell PJ, Nelson CC. A Biomarker and a Therapeutic Target: Investigating the Role of Glypican- in Prostate Cancer.

Poster: Philp LK, Rockstroh A, Lehman M, Otvos Jr L, Wade J, Nelson CC. Targeting the Adaptive Response in Adiponectin Receptor Signalling Following Androgen Targeted Therapy in Prostate Cancer: Efficacy in Castrate LNCaP Tumour Xenografts In vivo.

Poster: Stylianou N, Lehman ML, Wang C, Jovanovic L, Rockstroh A, Taherian Fard A,  Kashyap A, Fazli L, Buttyan R, Gleave M, Westbrook TF, Williams ED, Gunter JH , Nelson CC, Hollier BG*. Revealing the transcriptional landscape of epithelial-mesenchymal plasticity in mCRPC.

Poster: Hu Q, Ratther E, Williams ED, Sweeney K, Nelson CC, Russell PJ, Hollier BG. Alterations of tumor vasculature and oxygen level of prostate cancer xenografts in vivo assessed by ultrasound and photoacoustic imaging.

Poster: Chandra S, Srinivasan S, Clements J, Batra J. Elucidating the role of Hepatocyte Nuclear Factor  Beta (HNFB) transcript variants in prostate cancer.

Poster: Farashi S, O’Mara GT, Kryza T, Clements J, Jyotsna Batra J*. Causal variants that underlie miR-eQTLs in Prostate Cancer.

Poster: Subramaniam S, Jeet V, Walpole C, Nelson CC, Gunter JH, Clements JA, Batra J. Allele specific regulation of PDK by miRNAs in prostate cancer.

Poster: Matin F, Jeet V, Moya L, Selth LA, Chambers S, Australian Prostate Cancer BioResource, Clements JA, Batra J. A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer.

Poster: Srinivasan S, Buckle A, The Australian Prostate Cancer BioResource, Clements J, Batra J.      Functional analysis implicate a glycosylating prostate-cancer risk associated germline variant.

Poster: Batra J, Srinivasan S, Kryza T, Bock N, Stephens C, Dong Y, Panchadsaram J, Moya L, Röhl J, Perry-Keene JL, Buzacott K, Dadaev T, Brook MN, Lilja H, Spurdle A, Koistinen H, Stenman U, Kote-Jarai Z, Eeles R, The Practical Consortium, The Australian Prostate Cancer BioResource, Clements J. A functional variation in PSA (KLK) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with prostate cancer.

Poster: Maharaj M, Herington A, Stephenson SA. Expanding the SUMO gene stable with the identification of SUMO.

Poster: Joshi A, Rhee H, Pryor D, Lehman M, McKenzie I, Munns J, Malone G, Chung E, Heathcote P, Preston J, Lawson M, Wood S, Gustafson S,  Miles K, Vela I. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities - results of a multi-centre, prospective clinical trial.

Poster: Panchadsaram J, Tevz G, Rockstroh A, Taherian Fard A, Lehman M, Nelson C,The Australian Prostate Cancer BioResource, Clements J, Batra J. Functional analysis of GWAS identified p locus in prostate cancer.

Poster: Mehawed G, Choi W, Joshi A, Rhee H, Gustafson S, Miles K, Vela I. Initial Experience of Novel Hybrid PSMA PET / MRI imaging for lymph node staging in prostate cancer. In vitro culture and therapeutic profiling of patient derived metastatic prostate cancer.